Muzaffer Cicek

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo
    Muzaffer Cicek
    Endocrine Research Unit, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Res 67:10106-11. 2007
  2. ncbi Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
    J Cell Biochem 113:711-23. 2012
  3. ncbi TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways
    Muzaffer Cicek
    Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America
    PLoS ONE 6:e17522. 2011
  4. ncbi Breast cancer bone metastasis and current small therapeutics
    Muzaffer Cicek
    Endocrine Research Unit, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Cancer Metastasis Rev 25:635-44. 2006
  5. ncbi BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter
    Muzaffer Cicek
    Endocrine Research Unit, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Exp Metastasis 26:229-37. 2009
  6. ncbi Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin
    Steven Sizemore
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer Res 67:6183-91. 2007
  7. ncbi Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation
    Rajeev S Samant
    Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, USA
    Mol Cancer 6:6. 2007
  8. ncbi Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells
    Ryuichi Fukuyama
    Department of Cancer Biology, Cleveland Clinic, Cleveland, Ohio 44195, and School of Biomedical Sciences, Kent State University, USA
    Mol Carcinog 46:402-13. 2007
  9. ncbi Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients
    David G Hicks
    Department of Clinical and Anatomic Pathology, General Surgery-Breast Center, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin Cancer Res 12:6702-8. 2006
  10. ncbi Novel enhanced lung-colonizing variant of murine MBT-2 bladder cancer cells
    Minoru Horinaga
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 66:676-81. 2005

Collaborators

Detail Information

Publications13

  1. ncbi 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo
    Muzaffer Cicek
    Endocrine Research Unit, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Res 67:10106-11. 2007
    ..Our data support the conclusion that 2ME(2) could be an important new therapy in the arsenal to fight metastatic breast cancer...
  2. ncbi Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
    J Cell Biochem 113:711-23. 2012
    ..The use of the MC10 antibody, in combination with highly specific antibodies targeting only full-length ERβ, is likely to provide additional discriminatory features in breast cancers that may be useful in predicting response to therapy...
  3. ncbi TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways
    Muzaffer Cicek
    Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America
    PLoS ONE 6:e17522. 2011
    ..Together, these data provide evidence that TIEG1 controls osteoclast differentiation by reducing NFATc1 pathway activation and reduces osteoclast survival by suppressing AKT and MEK/ERK signaling...
  4. ncbi Breast cancer bone metastasis and current small therapeutics
    Muzaffer Cicek
    Endocrine Research Unit, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Cancer Metastasis Rev 25:635-44. 2006
    ..This review focuses on a brief discussion of tumor-driven osteolysis and the effects of small molecule therapies in reducing osteolytic tumor progression...
  5. ncbi BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter
    Muzaffer Cicek
    Endocrine Research Unit, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Exp Metastasis 26:229-37. 2009
    ....
  6. ncbi Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin
    Steven Sizemore
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer Res 67:6183-91. 2007
    ....
  7. ncbi Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation
    Rajeev S Samant
    Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, USA
    Mol Cancer 6:6. 2007
    ..BRMS1 is a member of mSin3-HDAC transcription co-repressor complex and has been shown to suppress the metastasis of breast cancer and melanoma cells in animal models. Hence we hypothesized that BRMS1 regulates OPN expression...
  8. ncbi Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells
    Ryuichi Fukuyama
    Department of Cancer Biology, Cleveland Clinic, Cleveland, Ohio 44195, and School of Biomedical Sciences, Kent State University, USA
    Mol Carcinog 46:402-13. 2007
    ....
  9. ncbi Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients
    David G Hicks
    Department of Clinical and Anatomic Pathology, General Surgery-Breast Center, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin Cancer Res 12:6702-8. 2006
    ..BRMS1 staining could potentially be used in patient stratification in conjunction with other prognostic markers. Further, mechanisms other than genomic deletion account for loss of BRMS1 gene expression in breast tumors...
  10. ncbi Novel enhanced lung-colonizing variant of murine MBT-2 bladder cancer cells
    Minoru Horinaga
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 66:676-81. 2005
    ..To develop an enhanced lung-colonizing variant of murine bladder cancer that will allow the mechanism of metastasis to be studied more readily...
  11. ncbi Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity
    Muzaffer Cicek
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    Cancer Res 65:3586-95. 2005
    ....
  12. ncbi The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin
    Anju Agarwal
    Department of Cancer Biology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Oncogene 24:1021-31. 2005
    ..These results indicate a role of this pathway in controlling gene expression important in tumor progression and metastasis...
  13. ncbi Identification of metastasis-associated proteins through protein analysis of metastatic MDA-MB-435 and metastasis-suppressed BRMS1 transfected-MDA-MB-435 cells
    Muzaffer Cicek
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Exp Metastasis 21:149-57. 2004
    ..Our results suggest that annexin I and alpha B-crystallin are important cellular proteins that are down regulated through BRMS1 mediated metastasis suppression...